MX350087B - Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7. - Google Patents

Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7.

Info

Publication number
MX350087B
MX350087B MX2014003295A MX2014003295A MX350087B MX 350087 B MX350087 B MX 350087B MX 2014003295 A MX2014003295 A MX 2014003295A MX 2014003295 A MX2014003295 A MX 2014003295A MX 350087 B MX350087 B MX 350087B
Authority
MX
Mexico
Prior art keywords
cells
methods
smad7 therapy
ccr9
monitoring responsiveness
Prior art date
Application number
MX2014003295A
Other languages
English (en)
Other versions
MX2014003295A (es
Inventor
Francesca Viti
Giovanni Monteleone
Salvatore Bellinvia
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MX2014003295A publication Critical patent/MX2014003295A/es
Publication of MX350087B publication Critical patent/MX350087B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para determinar la capacidad de respuesta de un sujeto que tiene Enfermedad Inflamatoria de Intestino (IBD) al tratamiento con por lo menos una terapia anti-Madres contra homólogo 7 de decapentaplégico (anti-SMAD7), el método caracterizado porque comprende: determinar la cantidad de por lo menos una población celular seleccionada del grupo que consiste de: linfocitos T receptor 9 de quimosina C-C+ (CCR9+) Forkhead Box P3+ (ForxP3+), linfocitos T CCR9+Interferón gamman+ (IFN-gamma+), linfocitos T CCR9+Interleucina 17A + (IL17A+), linfocitos TFoxP3+, linfocitos T IFN-gamma+ y linfocitos TIL17A +, en por lo menos una muestra de sangre periférica obtenida del sujeto, en donde, cantidades incrementadas de la población celular de linfocitos TCCR9+ FoxP3+, y/o cantidades reducidas de por lo menos una de las poblaciones celulares de linfocitos TCCR9+ IFN-gamma+, linfocitos T CCR9+ IL17A+, linfocitos T FoxP3+, linfocitos T IFN - gamma+ y linfocitos T IL17A+, en la por lo menos una muestra de sangre periférica en relación con un nivel de control conocido de la por lo menos una población celular, es predictiva de la capacidad de respuesta del sujeto que tiene IBD a la terapia anti-SMAD7. SMAD7; de CCR9+ FOXP3+ linfocitos T, CCR9+ IFN-gamma+ linfocitos T, CCR9+ IL17A+ linfocitos T, FOXP3+ linfocitos T, IFN-gamma+ linfocitos T, y/o IL17A-f linfocitos T.
MX2014003295A 2011-09-15 2012-09-14 Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7. MX350087B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11425234 2011-09-15
US201161576556P 2011-12-16 2011-12-16
PCT/EP2012/068146 WO2013037970A1 (en) 2011-09-15 2012-09-14 Methods for monitoring responsiveness to anti-smad7 therapy

Publications (2)

Publication Number Publication Date
MX2014003295A MX2014003295A (es) 2014-05-28
MX350087B true MX350087B (es) 2017-08-24

Family

ID=47882658

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003295A MX350087B (es) 2011-09-15 2012-09-14 Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7.

Country Status (12)

Country Link
US (2) US9791442B2 (es)
EP (2) EP3165929A3 (es)
JP (1) JP6389122B2 (es)
KR (1) KR102099990B1 (es)
CN (1) CN104040349B (es)
AU (1) AU2012307336B2 (es)
CA (1) CA2848595A1 (es)
ES (1) ES2617200T3 (es)
HK (1) HK1199095A1 (es)
MX (1) MX350087B (es)
RU (1) RU2678450C2 (es)
WO (1) WO2013037970A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RS56049B1 (sr) 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
WO2013158868A1 (en) 2012-04-18 2013-10-24 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
RU2674147C2 (ru) * 2013-03-15 2018-12-05 Ногра Фарма Лимитед Способы лечения колоректального рака
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
US20160139123A1 (en) * 2013-07-12 2016-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Shear Wave Imaging Method and Installation for Collecting Information on a Soft Solid
KR20170005058A (ko) * 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
WO2016059243A2 (en) * 2014-10-17 2016-04-21 Nogra Pharma Limmited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
WO2017019673A2 (en) * 2015-07-27 2017-02-02 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CA3000569A1 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
WO2017059225A1 (en) * 2015-09-30 2017-04-06 Celgene Corporation Tlr modulators and methods of use
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
US11619832B2 (en) 2018-03-08 2023-04-04 Coopervision International Limited Identification of contact lens wearers predisposed to contact lens discomfort
CN110082538B (zh) * 2019-04-19 2021-12-03 中山大学附属第六医院 CCR9+IL-17+Treg细胞在制备用于检测NEC的试剂盒中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
RU2185627C2 (ru) * 2000-09-11 2002-07-20 Новосибирская государственная медицинская академия Способ определения чувствительности (восприимчивости) к внутривенной лазеротерапии больных ишемической болезнью сердца
SI1456380T1 (sl) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad inhibitorji za zdravljenje cns bolezni
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
EP1913387B1 (en) 2005-08-02 2016-01-20 Centenary Institute of Cancer Medicine & Cell Biology Method for identifying regulatory t cells
AU2007224967A1 (en) * 2006-03-10 2007-09-20 Mount Sinai Hospital Diagnostic compositions and treatment methods for conditions involving trophoblast cell death, differentiation, invasion and/or cell fusion and turnover
US20090136470A1 (en) * 2007-06-13 2009-05-28 Hilde Cheroutre Regulatory t cells and methods of making and using same
US20110008795A1 (en) 2008-02-28 2011-01-13 Sysmex Corporation Marker for detection of il-17-producing helper t-cell, and method for detection of il-17-producing helper t-cell
JP2010051307A (ja) * 2008-07-28 2010-03-11 Eisai R & D Management Co Ltd Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法
RS56049B1 (sr) 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
HUE028240T2 (en) 2009-07-10 2016-12-28 Transgene Sa Biomarker Patient Selection and Related Procedures
US8766034B2 (en) * 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
WO2013158868A1 (en) 2012-04-18 2013-10-24 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2674147C2 (ru) 2013-03-15 2018-12-05 Ногра Фарма Лимитед Способы лечения колоректального рака
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
WO2016059243A2 (en) 2014-10-17 2016-04-21 Nogra Pharma Limmited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
CA3000569A1 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Also Published As

Publication number Publication date
EP3165929A3 (en) 2017-06-21
CA2848595A1 (en) 2013-03-21
WO2013037970A1 (en) 2013-03-21
AU2012307336A1 (en) 2014-03-27
US20180128829A1 (en) 2018-05-10
JP6389122B2 (ja) 2018-09-12
KR20140059859A (ko) 2014-05-16
RU2678450C2 (ru) 2019-01-29
EP2748611B1 (en) 2016-11-23
JP2014531584A (ja) 2014-11-27
RU2014114838A (ru) 2015-10-20
US20150148245A1 (en) 2015-05-28
US9791442B2 (en) 2017-10-17
ES2617200T3 (es) 2017-06-15
AU2012307336B2 (en) 2017-08-24
MX2014003295A (es) 2014-05-28
HK1199095A1 (en) 2015-06-19
EP2748611A1 (en) 2014-07-02
KR102099990B1 (ko) 2020-04-13
EP3165929A2 (en) 2017-05-10
CN104040349A (zh) 2014-09-10
NZ622067A (en) 2016-05-27
CN104040349B (zh) 2017-07-04
NZ719884A (en) 2020-02-28

Similar Documents

Publication Publication Date Title
MX2014003295A (es) Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7.
MX2016005908A (es) Metodos para determinar estado de carga y electrodos de referencia de calibracion en una bateria de flujo de redox.
GB2508124A (en) Methods and systems to determine a context of a device
NZ608208A (en) Breast cancer diagnostics
BR112012016119B1 (pt) método de detecção de células em uma amostra, dispositivo unitário de preparação e detecção de amostra e kit
NZ621733A (en) Lung cancer biomarkers and uses thereof
MX2017005750A (es) Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso.
MX2014004906A (es) Analisis y control de flujo de aerosol.
MX2013001293A (es) Ensayos biomarcadores para detectar o medir inhibicion de actividad quinasa tor.
UY34317A (es) Anticuerpo antireceptor de célula T (alfa)/ß
MX2018000303A (es) Sistema y metodo de valoracion de la funcion endotelial.
BR112013021590A2 (pt) detecção de capacitância em ensaio eletroquímico com resposta otimizada
EP2531860A4 (en) MEASURING MULTIPLE ANALYTE SAMPLES USING AN ONLINE CIRCULATING TANK
GB201009175D0 (en) Determining an indication of a background level of utility consumption
SG195256A1 (en) Alkylamino bodipy dyes as selective fluorescent probes for proteins andmouse embryonic stem cells
MX2015014892A (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
WO2014004609A3 (en) Rapid assays for t-cell activation by rna measurements using flow cytometry
GB201206977D0 (en) An enzyme detection device
MX2017006831A (es) Sistemas y metodos para la determinacion electroquimica de hematocrito mediante determinaciones de angulos de fase de impedancia de corriente alterna.
PT2936164T (pt) Automação de incubação, processamento, recolha e análise de amostras numa placa multicelular com suporte de amostra de película fina
MX2015001717A (es) Metodo para la deteccion directa de mycobacterium tuberculosis.
IN2014CN04521A (es)
MX2015002694A (es) Permeabilidad de la celda de flujo y sistema de conductancia hidraulica.
WO2012054284A3 (en) Interferon gene signature and methods of use thereof
MX353243B (es) Metodo para incrementar la secrecion de proteinas recombinantes.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration